55592-81-9

Basic information

• Product Name: N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide
• Synonyms: N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide
• CAS NO: 55592-81-9
• Molecular Weight: 379.456
• Mol File: 55592-81-9.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide(55592-81-9)
• EPA Substance Registry System: N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide(55592-81-9)

Safety Data

• Hazardous Substances Data: 55592-81-9(Hazardous Substances Data)

Upstream product

• 126583-16-2 Boc-Lys(Z)-OCOOEt 
• 34404-36-9 Boc-Lys(Z)-OSu 
• 73548-77-3 Boc-L-Lys(Z)-OMe 
• 84890-96-0 C₂₄H₃₆N₂O₈ 
• 50903-59-8 N-t-butyloxycarbonyl-Nε-benzyloxycarbonyl-lysine pentafluorophenyl ester 
• 2389-45-9 Boc-Lys(Z)-OH 
• 2389-46-0 N-α-tert-butyloxycarbonyl-N-ε-benzyloxycarbonyl-lysine p-nitrophenyl ester 
• 2389-45-9 6-(((benzyloxy)carbonyl)amino)-2-((tert butoxycarbonyl)amino)-hexanoic acid 

Downstream Products

• 324748-31-4 Boc-Lys(Z)(S)-NH₂ 
• 1340480-93-4 Nα-[4-chlorocinnamoyl-L-alanyl-D-isoglutaminyl]-L-lysine 
• 244778-27-6 (5-tert-butoxycarbonylamino-5-cyano-pentyl)-carbamic acid benzyl ester 
• 58117-53-6 Nε-Cbz-L-lysine hydrochloride 
• 1426335-33-2 benzyl tert-butyl ((S)-6-oxo-6-(((2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)hexane-1,5-diyl)dicarbamate 
• 1286246-27-2 Nα-[4-chlorocinnamoyl-L-alanyl-D-isoglutaminyl]-L-lysine 
• 1177408-24-0 C₃₈H₅₅N₅O₁₀ 
• 50557-87-4 N^α-Acetyl-N^ε-benzyloxycarbonyl-L-lysinamid 
• 61125-53-9 Biocytinamid 

Relevant articles and documents

DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA

Disclosed are deuterated analogs of SBT-20 and elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.

Solution-phase synthesis of a muramyl dipeptide analogue MDA

The solution-phase synthesis of a muramyl dipeptide (MDP) analogue of Nα-[4-chlorocinnamoyl-l-alanyl-d-isoglutaminyl]-l-lysine (MDA, 2) is reported that possesses the features of easy feasibility, safety and low cost in large scale of synthesis.